Page 11 - Cost Plus News Today

Magic mushrooms for depression. $1 hearing aids. Meds for 85 percent less. These are just a few of the advances these healthcare disruptors are engineering.

Excited physicians discuss the healthcare disruptors driving rapid change in the industry, such as fixed-profit pharmacy companies, AI in ICU therapeutics and more.

The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

–  YUSIMRY™ will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on costplusdrugs.com... | June 1, 2023

01.06.2023 - –  YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees  – DALLAS, Texas and REDWOOD CITY, ... Seite 1

–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on...

Billionaire entrepreneur Mark Cuban primarily relayed anecdotes and lessons from his business career, but also had some colorful language for politicians his conversation at the Mackinac Policy Conference.

In a recent escalation of their ongoing feud, leftist billionaire  Mark Cuban has accused Elon Musk, the most followed person on Twitter along with its new owner, of manipulating the platform's algorithm to promote his own tweets and viewpoints.

In a recent escalation of their ongoing feud, leftist billionaire  Mark Cuban has accused Elon Musk, the most followed person on Twitter along with its new owner, of manipulating the platform's algorithm to promote his own tweets and viewpoints.